Rat Aortic Endothelial Cells: RAOEC, adult
SIGMA/R304-05A
Synonym: RAOEC cells
Product Type: Product-on-demand
Rat Aortic Endothelial Cells: RAOEC
| biological source | rat aorta (adult) |
| growth mode | Adherent |
| manufacturer/tradename | Cell Applications, Inc |
| morphology | Endothelial |
| packaging | pkg of 500,000 cells |
| relevant disease(s) | diabetes; cardiovascular diseases |
| storage temp. | −196°C |
| technique(s) | cell culture | mammalian: suitable |
| Analysis Note: | Each lot was tested for proper morphology, Population Doublings, Negative for HIV, Hepatitis B, Hepatitis C, mycoplasma, bacteria, and fungi. |
| Application: | Cardiovascular function, studies on immune system and graft rejection, development of 3D endothelialized engineered tissues, drug discovery, stent-graft compatibility testing. |
| Biochem/physiol Actions: | Aorta |
| General description: | Lot specific orders are not able to be placed through the web. Contact your local sales rep for more details. RAOEC from Cell Applications, Inc. provide a useful model system to study many aspects of cardiovascular function and disease. Co-culture of the artery endothelial cells with species-matched smooth muscle cells provides an ideal model for studying the interaction between these two cell types. RAOEC from Cell Applications, Inc. have been utilized in a number of research publications to: • Investigate critical signaling pathways and mechanisms relevant to proper endothelial function, such as angiogenesis, proliferation, permeability, and search for beneficial modulators for therapeutic use (Sorensen, 2008; Liu, 2009; Makino, 2009; Masuda, 2012; Gros, 2013; Nguen, 2013) • Elucidate molecular mechanisms of various cardiovascular risk factors, including those associated with diabetes, polycystic kidney disease, treatment for allograft rejection and vascular ER stress (Makino, 2008; Chiasson, 2011, Ren, 2011; Padilla, 2013) • Provide a gold standard control for endothelial markers vWF and PECAM/CD31 expression (Hanley, 2008; Imamura, 2010) • Develop drug delivery system for thrombolytic treatment (Mei, 2010)and methods for cardiac regeneration (Lionetti, 2010); design better vascular implants (Ibrahim, 2008; Yao, 2008; Duffy, 2011) and bone tissue engineering (Hamid, 2014) Additionally, RAOEC from Cell Applications, Inc. were used to investigate the reasons for differential effects of Intermedin (IMD) on permeability of endothelial cells from different vascular beds (Aslam, 2011). Specifically, it was shown that IMD increased permeability of rat coronary microvascular endothelial cells by inducing loss of VE-cadherin from cel-cell junctions, but it reduced permeability of RAOEC and HUVECs because in those cell types IMD instead caused accumulation of VE-cadherin in cell-cell junctions. These differential effects of IMD on VE-cadherin are explained by the fact that, although IMD activates cAMP/PKA and inhibits RhoA/ROCK pathways leading to rearrangement of actin in both cell types, it only causes downstream Rac1 inhibition in rat coronary microvascular endothelial cells, but not in RAOEC or HUVEC. These results highlight the fundamental differences between endothelial cells from different vascular beds and/or microvascular vs. macrovascular endothelia. |
| Other Notes: | Rat Endothelial Cell Basal Medium that contains 10% FBS and 10% DMSO |
| Preparation Note: | • 3rd passage, >500,000 cells in Rat Endothelial Cell Basal Medium that contains 10% FBS and 10% DMSO • Can be cultured at least to 6th passage |
| Preparation Note: | Please refer to the RAOEC Culture Protocol   . |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −196°C |
| UNSPSC | 41106514 |